Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $48.8 million.

  • Kura Oncology's Current Deferred Revenue changed N/A to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year change of. This contributed to the annual value of $24.3 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Current Deferred Revenue is $48.8 million.
  • Kura Oncology's Current Deferred Revenue's 5-year high stood at $49.4 million during Q2 2025, with a 5-year trough of $24.3 million in Q4 2024.